NCT00249821View on ClinicalTrials.gov

Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Small Gestational Age (SGA)
Interventions
DRUG

Saizen®

Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

DRUG

Saizen®

Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

All Listed Sponsors
collaborator

Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany

UNKNOWN

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00249821 - Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age | Biotech Hunter | Biotech Hunter